Rational design and engineering of therapeutic proteins

被引:147
作者
Marshall, SA [1 ]
Lazar, GA [1 ]
Chirino, AJ [1 ]
Desjarlais, JR [1 ]
机构
[1] Xencor, Monrovia, CA 91016 USA
关键词
D O I
10.1016/S1359-6446(03)02610-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An increasing number of engineered protein therapeutics are currently being developed, tested in clinical trials and marketed for use. Many of these proteins arose out of hit-and-miss efforts to discover specific mutations, fusion partners or chemical modifications that confer desired properties. Through these efforts, several useful strategies have emerged for rational optimization of therapeutic candidates. The controlled manipulation of the physical, chemical and biological properties of proteins enabled by structure-based simulation is now being used to refine established rational engineering approaches and to advance new strategies. These methods provide clear, hypothesis-driven routes to solve problems that plague many proteins and to create novel mechanisms of action. We anticipate that rational protein engineering will shape the field of protein therapeutics dramatically by improving existing products and enabling the development of novel therapeutic agents.
引用
收藏
页码:212 / 221
页数:10
相关论文
共 68 条
[1]   Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD [J].
Ågren, L ;
Norin, M ;
Lycke, N ;
Löwenadler, B .
PROTEIN ENGINEERING, 1999, 12 (02) :173-178
[2]  
Antonelli G, 1999, EUR CYTOKINE NETW, V10, P413
[3]   CYSTEINE-17 OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IS PARTIALLY SOLVENT-EXPOSED [J].
ARAKAWA, T ;
PRESTRELSKI, SJ ;
NARHI, LO ;
BOONE, TC ;
KENNEY, WC .
JOURNAL OF PROTEIN CHEMISTRY, 1993, 12 (05) :525-531
[4]  
Baca M, 1997, J BIOL CHEM, V272, P10678
[5]   Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[6]   Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].
Chen, Y ;
Wiesmann, C ;
Fuh, G ;
Li, B ;
Christinger, HW ;
McKay, P ;
de Vos, AM ;
Lowman, HB .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881
[7]   Long-acting growth hormones produced by conjugation with polyethylene glycol [J].
Clark, R ;
Olson, K ;
Fuh, G ;
Marian, M ;
Mortensen, D ;
Teshima, F ;
Chang, S ;
Chu, H ;
Mukku, V ;
CanovaDavis, E ;
Somer, T ;
Cronin, M ;
Winkler, M ;
Wells, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (36) :21969-21977
[8]   Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life [J].
Culajay, JF ;
Blaber, SI ;
Khurana, A ;
Blaber, M .
BIOCHEMISTRY, 2000, 39 (24) :7153-7158
[9]   Protein design automation [J].
Dahiyat, BI ;
Mayo, SL .
PROTEIN SCIENCE, 1996, 5 (05) :895-903
[10]   Automated design of the surface positions of protein helices [J].
Dahiyat, BI ;
Gordon, DB ;
Mayo, SL .
PROTEIN SCIENCE, 1997, 6 (06) :1333-1337